Table 2.
Incidence of Outcomes
| Outcome | TMP-SMX Exposed (n = 12064) | TMP-SMX Unexposed (n = 107335) | ||
|---|---|---|---|---|
| Cases (n) | Incidencea (per 10000 PY) | Cases (N) | Incidencea (per 10000 PY) | |
| Pneumocystis jirovecii infectiona | 1 | 0.61 | 5 | 0.53 |
| Cutaneous hypersensitivity reaction | 205 | 125 | 808 | 86 |
| Myelosuppression | 386 | 235 | 1842 | 197 |
Abbreviations: IQR, interquartile range; PY, person-years; TMP-SMX, trimethoprim-sulfamethoxazole.
aOne patient in the TMP-SMX–unexposed group was treated with an alternative prophylaxis agent before P jirovecii pneumonia infection. The patient then was treated with TMP-SMX after developing P jirovecii pneumonia infection.